Hypersensitivity II — Type II
← Back 📋 Q-Bank 🏠 All Units
HIGH YIELD ★★★
Clinical Immunology · Unit 14 of 17

Hypersensitivity II — Type II

TMU Type II Hypersensitivity deck — Yu Chunyan, Department of Immunology Janeway's Immunobiology 10e Owns MCQ Q19 and True/False Q7 and Q10
01

Antibody against a cell ★★★

Type I was antibody sitting on a mast cell, waiting for antigen to arrive. Type II is the reverse: antibody binding an antigen that is already on a cell surface — and the cell carrying that antigen is then destroyed. The defining feature, and the one the exam asks about, is that there is a specific target cell.

ComponentDetail
AntibodiesIgG and IgM
AntigenPresent on the cell surface
EffectorsComplement, macrophages and NK cells
Cells affectedBlood cells and self tissue cells
⭐ Two exam items define this unit
“In the following diseases, which one has target cell damage?” A. Asthma   B. Contact dermatitis   C. Hemolytic disease   D. Rheumatoid arthritis
Haemolytic disease. Type II is defined by antibody binding a specific target cell and destroying it. In asthma (type I) the mast cell degranulates but is not itself destroyed; in contact dermatitis (type IV) T cells damage tissue diffusely; in rheumatoid arthritis (type III) immune complexes deposit in synovium — no single target cell is marked.

⚠️ The original paper misprints this question: two options are both labelled “B”. It is reproduced here with corrected lettering.
Past Papers 2019 & 2020, Section III Q19
True or false: “NK cells, macrophages and complements are involved in type II hypersensitivity.”
TRUE. All three effector routes appear in §3: complement-mediated lysis, opsonised phagocytosis by macrophages, and ADCC by NK cells. Contrast MCQ Q17 in Unit 13, where the NK cell is the wrong answer for type I — the difference is that ADCC needs IgG on a target cell, which type II has and type I does not.
Past Papers 2019 & 2020, Section IV Q10
Test yourself
  • Which antibodies mediate type II? → IgG and IgM
  • Where is the antigen? → On the cell surface
  • Which effectors are involved? → Complement, macrophages and NK cells
  • What is the defining feature? → Damage to a specific target cell
02

Where the surface antigen comes from ★★

  • Constitutive components of the cell membraneABO blood group antigens, Rh blood group antigens, HLA antigens
  • Common antigens shared by host cells with exogenous antigens — for example the cell wall of streptococcus and the cardiac valve
  • Modified self antigens — altered by chemicals, infections or drugs
  • Antigens or haptens adsorbed to the cell surface

Category 2 should look familiar — it is Unit 2's cross-reaction and molecular mimicry, reappearing as a disease mechanism. Antibody raised legitimately against a streptococcus binds a cardiac valve because the two share an epitope. Category 4 is Unit 2's hapten: a drug adsorbed onto a red cell can make that cell a target, which is how drug-induced haemolytic anaemia happens.

Test yourself
  • Name the four sources of type II antigen. → Constitutive membrane components; shared/cross-reactive antigens; modified self antigens; adsorbed antigens or haptens
  • Give an example of a constitutive one. → ABO, Rh or HLA antigens
  • Which category explains drug-induced haemolytic anaemia? → Haptens adsorbed to the cell surface
03

Three ways to destroy the target ★★★

MechanismHow it works
1 · Complement-mediated lysisIgG or IgM on the cell surface activates the classical pathway; the MAC (C5b–C9) lyses the target cell
2 · Opsonised phagocytosisThe coated cell is phagocytosed — via FcγR binding the antibody, and via C3b binding complement receptors on macrophages and neutrophils
3 · ADCCNK cells bind the IgG coating the target through FcγRIII (CD16) and kill it
Nothing here is new — that is the point

Look at the three mechanisms and notice that every one is a normal antibody effector function from Unit 3, working perfectly. Complement lysis is what antibody does to bacteria. Opsonisation is how phagocytes clear infection. ADCC is how NK cells kill virus-infected cells.

The pathology is entirely in the target. The machinery is not malfunctioning — it has simply been aimed at a host cell. That is why type II diseases are so destructive and so hard to switch off: there is nothing broken to repair.

Test yourself
  • Name the three mechanisms of type II damage. → Complement-mediated lysis, opsonised phagocytosis, ADCC
  • Which complement product lyses the cell? → The MAC, C5b–C9
  • Which two opsonins drive phagocytosis? → Antibody via FcγR, and C3b via complement receptors
  • Which cell performs ADCC, and via which receptor? → The NK cell, via FcγRIII (CD16)
04

Transfusion reactions ★★

Detail
ScenarioA type A individual transfused with blood from a type B individual
MechanismRed cells + IgMcomplement activation
SymptomsHaemolysis, fever, chills, nausea, clotting within blood vessels, pain in the lower back, haemoglobin in the urine
TherapyTerminate the transfusion; maintain urine flow with diuretics

Note that the antibody here is IgM. Anti-A and anti-B are the natural antibodies mentioned in Unit 3 — present without prior transfusion, and IgM because they arise against carbohydrate (TI) antigens with no class switching. Being IgM, they are outstanding complement activators, which is why ABO incompatibility causes immediate intravascular haemolysis rather than a slow process.

Test yourself
  • Which antibody causes an ABO transfusion reaction? → IgM
  • What is the mechanism? → IgM on red cells activates complement, causing lysis
  • Name the key symptoms. → Haemolysis, fever, chills, nausea, intravascular clotting, lower back pain, haemoglobinuria
  • What is the therapy? → Stop the transfusion and maintain urine flow with diuretics
  • Why is ABO haemolysis so rapid? → Anti-A/anti-B are IgM, the most efficient complement activator
05

Haemolytic disease of the newborn ★★★

HDN is the most instructive disease in the whole course, because solving it requires almost everything taught so far — primary versus secondary responses, memory cells, class switching, and which immunoglobulin crosses the placenta.

Haemolytic disease of the newborn (HDN)

Disease caused by Rh or ABO blood-group incompatibility between mother and fetus. It develops when maternal IgG against fetal blood-group antigen crosses the placenta and destroys fetal red blood cells. Consequences: fetal anaemia, jaundice and bilirubin deposition.

Why the FIRST baby is safe and the second is not
  1. An Rh⁻ mother carries an Rh⁺ fetus.
  2. Fetal Rh⁺ red cells enter the mother — at delivery of the first baby, or through transfusion or abortion.
  3. The mother mounts a primary response: IgM, which cannot cross the placenta. The first baby is therefore unharmed. But memory cells are formed.
  4. In a subsequent pregnancy with an Rh⁺ fetus, those memory cells mount a secondary response: IgG, at high titre.
  5. IgG crosses the placenta, binds fetal red cells, and lyses them → haemolytic disease of the newborn.

Every step is Unit 12's primary-versus-secondary table and Unit 3's placental-transfer rule, applied to a real disease.

The disease is a secondary immune response happening to the wrong person

Trace the logic and notice how neatly it explains the clinical facts.

Why is the first baby spared? Because a primary response makes IgM, and IgM is a 900 kD pentamer that cannot cross the placenta. The sensitising event usually happens at delivery, when the baby is already out.

Why is the second baby affected? Because memory cells produce IgG — and IgG is the one class that crosses the placenta. The mechanism that normally gives a newborn passive immunity is the same one that destroys its red cells.

So the target is the mother's memory. If you prevent memory forming, there is never a secondary response — which is exactly what the prevention does.

ConsequenceMechanism
AnaemiaMild, severe or fatal — from red cell destruction
JaundiceFrom released haemoglobin
Brain damageHaemoglobin → lipid-soluble bilirubin → accumulates in the brain
⭐ True/False Q7 — set in both papers
“Hemolytic disease of newborn caused by Rh antigen incompatibility can be prevented by administrating Anti-Rh antibody (Rhogam) in mother within 72 hours after the first delivery.”
TRUE. The mechanism is elegant: Rhogam binds the Rh antigen on fetal red cells in the mother's circulation and clears them before her immune system can respond. That prevents B-cell activation and memory-cell generation — so no memory means no secondary response, and no IgG in the next pregnancy.

The 72-hour window matters: it must be given before sensitisation is established. This is passive immunisation used not to protect the recipient but to prevent an immune response — the only place in the course where antibody is given for that purpose.
Past Papers 2019 & 2020, Section IV Q7
TherapyPurpose
Intrauterine blood-exchange transfusionReplace fetal Rh⁺ red cells with Rh⁻ cells
Blood-exchange transfusionPrimarily to remove bilirubin
Low-level UV light (phototherapy)Break down bilirubin and prevent cerebral damage
PlasmapheresisDiscard the maternal plasma containing anti-Rh antibody
Test yourself
  • What causes HDN? → Maternal IgG against fetal blood-group antigen crossing the placenta and destroying fetal red cells
  • Why is the first baby usually unaffected? → The primary response makes IgM, which cannot cross the placenta
  • How does the mother become sensitized? → Fetal Rh⁺ cells entering her at delivery, or by transfusion or abortion
  • How does Rhogam work? → It binds fetal Rh antigen and clears the cells before B-cell activation and memory formation
  • Within what time must Rhogam be given? → 72 hours after the first delivery
  • Why does bilirubin damage the brain? → It is lipid-soluble and accumulates in brain tissue
06

Revision layer

The exam map for this unit

SectionItemFrom
III. MCQ Q19Haemolytic disease shows target-cell damage§1
IV. True/False Q7Rhogam within 72 h prevents HDN — T§5
IV. True/False Q10NK cells, macrophages and complement act in type II — T§3

The whole unit on one screen

QuestionAnswer
Antibodies?IgG and IgM
Antigen location?On the cell surface
Effectors?Complement · macrophages · NK cells
Three mechanisms?Complement lysis (MAC) · opsonised phagocytosis · ADCC
Four antigen sources?Constitutive membrane · shared/cross-reactive · modified self · adsorbed haptens
Transfusion reaction antibody?IgM, activating complement
Transfusion therapy?Stop the transfusion; maintain urine flow with diuretics
Why is the first baby spared in HDN?Primary response is IgM — cannot cross the placenta
Why is the second affected?Memory → secondary response → IgG — crosses the placenta
Rhogam mechanism and timing?Clears fetal Rh⁺ cells before B-cell activation, preventing memory; within 72 h
Diseases?Transfusion reaction · HDN · haemolytic anaemia · hyperthyroidism
Test yourself — the whole unit
  • Define type II hypersensitivity. → IgG or IgM binding antigen on a cell surface, causing that target cell's destruction
  • Name the three destruction mechanisms. → Complement-mediated lysis, opsonised phagocytosis, ADCC
  • Which cell performs ADCC here, and why not in type I? → The NK cell via CD16 — ADCC needs IgG on a target cell, which type I lacks
  • Trace HDN from first to second pregnancy. → Fetal Rh⁺ cells sensitize mother → IgM (no placental transfer, first baby safe) → memory → second pregnancy → IgG crosses → fetal red cells lysed
  • How is HDN prevented, and why does it work? → Rhogam within 72 h clears the fetal cells before memory can form
  • Which disease is the answer to 'target cell damage'? → Haemolytic disease